RxDoctor Payments Data

Kevin Dougherty, MD

Internal Medicine · Raleigh, NCNPI 1922186998

Payments from drug & device makers

$2,550in general payments, 2019–2025

Across 168 payments — averaging $15.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$495
  • Lilly USA, LLC$299
  • Amgen$253
  • Johnson & Johnson$170
  • Astellas Pharma US Inc$169
  • Abbott$167
  • plus $996 from 18 others

What the payments were for

  • Food & beverage$2,550100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,550 in reported general payments places this provider in the 80th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$204,344
Medicare patients
208
Services billed
10,013

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin106$128,962
MounjaroTirzepatide91$111,897
EliquisApixaban101$107,364
OzempicSemaglutide66$87,724
GemtesaVibegron46$29,986
RybelsusSemaglutide26$24,491
JanuviaSitagliptin Phosphate24$22,540
ArexvyRsvpref3 Antigen/As01e/Pf50$15,879
TradjentaLinagliptin18$15,276
Tresiba Flextouch U-200Insulin Degludec18$15,131
Testosterone68$14,393
XareltoRivaroxaban17$14,278
ShingrixVaricella-Zoster Ge/As01b/Pf63$13,979
EntrestoSacubitril/Valsartan13$13,542
TrulicityDulaglutide11$10,327

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$156$144,238124 claims
Lilly USA, LLCMounjaro, Trulicity$299$122,224102 claims
Novo NordiskOzempic, Rybelsus$495$112,21692 claims
PfizerEliquis$136$107,364101 claims
GSKArexvy, Shingrix$58$29,858113 claims
MerckJanuvia$55$22,54024 claims
Johnson & JohnsonXarelto$170$14,27817 claims
NovartisEntresto$51$13,54213 claims
Astellas Pharma US IncMyrbetriq$169$8,99614 claims
AbbVieSynthroid$99$3,13040 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →